Immunome (IMNM) Return on Sales (2023 - 2025)
Immunome (IMNM) has disclosed Return on Sales for 3 consecutive years, with 32.29% as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Return on Sales fell 199.0% year-over-year to 32.29%, compared with a TTM value of 32.29% through Dec 2025, up 154.0%, and an annual FY2025 reading of 32.29%, up 154.0% over the prior year.
- Return on Sales was 32.29% for Q4 2025 at Immunome, down from 24.2% in the prior quarter.
- Across five years, Return on Sales topped out at 1.3% in Q3 2023 and bottomed at 128.57% in Q1 2024.
- Average Return on Sales over 3 years is 25.48%, with a median of 17.14% recorded in 2024.
- The sharpest move saw Return on Sales crashed -12668bps in 2024, then soared 11332bps in 2025.
- Year by year, Return on Sales stood at 24.74% in 2023, then dropped by -22bps to 30.3% in 2024, then fell by -7bps to 32.29% in 2025.
- Business Quant data shows Return on Sales for IMNM at 32.29% in Q4 2025, 24.2% in Q3 2025, and 11.58% in Q2 2025.